Huey Edward D, Mirza Nadeem, Putnam Karen T, Soares Holly, Csako Gyorgy, Levy James A, Copenhaver Brittany, Cohen Robert M, Sunderland Trey
Geriatric Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, USA.
Dement Geriatr Cogn Disord. 2006;22(1):48-53. doi: 10.1159/000093261. Epub 2006 May 8.
Cerebrospinal fluid (CSF) measures of beta-amyloid(1-42 )and tau differ between patients with Alzheimer's Disease (AD) and elderly normal controls. The effect of time and APOE genotype on these biomarkers continues to be elucidated.
We assessed CSF beta-amyloid(1-42) and tau in 20 mild-to-moderate AD patients, 11 APOE epsilon4+ and 9 APOE epsilon4-, over a mean time of 3.8 years (range 1-11.1 years).
Over the period measured, CSF beta-amyloid(1-42) levels were lower in APOE epsilon4+ compared to APOE epsilon4- patients, and the levels decreased over time. Tau levels were stable over time and did not show an effect of APOE allele.
While this is a limited clinical sample, the further decrease in CSF beta-amyloid(1-42 )(i.e., more abnormal) combined with the CSF tau stability over a mean period of almost 4 years suggests that beta-amyloid(1-42 )and tau maintain their potential usefulness as diagnostic biomarkers over time. These findings should be taken into account if CSF beta-amyloid(1-42) and tau are used as measures of treatment response.
阿尔茨海默病（AD）患者与老年正常对照者的脑脊液（CSF）中β-淀粉样蛋白（1-42）和tau蛋白的测量值存在差异。时间和APOE基因分型对这些生物标志物的影响仍有待阐明。
我们评估了20例轻度至中度AD患者的脑脊液β-淀粉样蛋白（1-42）和tau蛋白，其中11例携带APOE ε4等位基因，9例不携带，平均随访时间为3.8年（范围1-11.1年）。
在测量期间，携带APOE ε4等位基因的患者脑脊液β-淀粉样蛋白（1-42）水平低于不携带该等位基因的患者，且该水平随时间下降。tau蛋白水平随时间保持稳定，未显示出APOE等位基因的影响。
虽然这是一个有限的临床样本，但脑脊液β-淀粉样蛋白（1-42）水平进一步下降（即更异常），同时脑脊液tau蛋白在近4年的平均时间内保持稳定，这表明β-淀粉样蛋白（1-42）和tau蛋白作为诊断生物标志物随时间推移仍具有潜在的效用。如果将脑脊液β-淀粉样蛋白（1-42）和tau蛋白用作治疗反应的指标，应考虑这些发现。
Zotero 插件